Gilead (GILD) Q1 2026 earnings review
Core Business Accelerates, But M&A Spree Wipes Out 2026 Earnings
Gilead's commercial engine is firing on all cylinders. Driven by the successful launch of Yeztugo and Descovy's strength, HIV sales accelerated to 10% YoY growth. This pushed base product sales (ex-Veklury) up 8%, prompting management to raise full-year revenue guidance. However, the company's aggressive pipeline expansion strategy carries a staggering near-term price tag. Gilead acquired Arcellx, Ouro, and Tubulis, triggering an $11.5 billion acquired IPR&D charge. This completely hijacked the 2026 bottom-line narrative, slashing full-year Non-GAAP EPS guidance from a healthy $8.65 midpoint to a net loss of $(0.85).
🐂 Bull Case
Total HIV sales grew 10% YoY to $5.03 billion. Descovy surged 38% and Biktarvy grew 7%, proving the core business is highly durable and gaining market share despite broader macro headwinds.
Excluding the massive one-time M&A charges, underlying operations are highly profitable. Non-GAAP product gross margins expanded 200 basis points YoY to 87.5%.
🐻 Bear Case
The $11.5B IPR&D hit reflects a massive bet on Anito-cel and other early-stage assets. If these face the same competitive roadblocks as Gilead's legacy cell therapies, the ROI will be severely negative.
Once touted as a primary growth pillar, cell therapy revenues declined 12% YoY. Yescarta dropped 14%, losing ground to fierce in-class and out-of-class competition.
⚖️ Verdict: ⚪
Neutral. The underlying commercial engine is accelerating flawlessly, and the 8% base revenue growth is impressive. However, the staggering $11.5B accounting hit from acquisitions and the continuous decay of the cell therapy franchise demand caution.
Key Themes
HIV Franchise Accelerates with Yeztugo
The HIV segment is accelerating, with sales jumping 10% YoY to $5.03 billion (up from 6% growth in 25Q4). Biktarvy grew 7% to $3.4 billion, but the standout was Descovy, which surged 38% to $807 million. The successful launch of Yeztugo (lenacapavir) is significantly expanding the prevention market, driving higher overall demand and average realized pricing.
Trodelvy Rebounds Sharply
After sequential softness late last year, Trodelvy sales re-accelerated, jumping 37% YoY to $402 million. Management cited higher demand, favorable inventory dynamics, and a higher average realized price. This reverses concerns from previous quarters and stabilizes the oncology growth narrative.
Aggressive Oncology M&A Expansion
Gilead is drastically expanding its oncology and inflammation pipeline through rapid M&A. The company completed the $7.8 billion acquisition of Arcellx (securing anito-cel for multiple myeloma) and agreed to acquire Tubulis (adding the NaPi2b-directed ADC TUB-040) and Ouro (T-cell engagers). While this secures best-in-disease potential, it requires flawless future execution to justify the price tag.
Cell Therapy Franchise Decelerating Rapidly
Management touts oncology growth from M&A, but this narrative is contradicted by their legacy cell therapy business, which is collapsing. Sales fell 12% YoY to $407 million. Yescarta dropped 14% to $332 million due to fierce in-class and out-of-class competition. This marks the fifth consecutive quarter of YoY declines for the segment, representing a severe break in the growth trend.
M&A Spree Wipes Out Earnings
The aggressive M&A strategy triggered $11.5 billion in acquired IPR&D and financing charges. This completely reversed the company's profitability outlook for FY26, flipping guidance from an expected $8.65 EPS profit to a $(0.85) loss. Investors must now endure a year of deeply negative reported earnings while waiting for pipeline execution.
Gross Margin Expansion
A major bright spot in the quarter was operational efficiency. Non-GAAP product gross margin expanded to 87.5%, up 200 basis points from 85.5% in 25Q1. Management attributed this highly profitable mix shift to the expiration of a royalty-related obligation and stronger demand in high-margin segments.
Macro and Policy Headwinds
Gilead continues to operate against significant macro policy friction. The company specifically highlighted ongoing risks from Medicare Part D pricing reform under the Inflation Reduction Act, the expiration of ACA subsidies, and potential tariff impacts. While the HIV segment grew impressively despite these known headwinds, pricing pressure remains a structural long-term risk.
Other KPIs
Stable and highly cash-generative. The core business generated enough free cash flow to support $1.0 billion in dividends, $2.8 billion in debt repayments, and $419 million in share repurchases, keeping the balance sheet robust despite heavy M&A activity.
Decelerating. COVID-19 related sales continue their structural decay, falling 52% YoY. While expected, it remains a persistent drag on total top-line growth, obscuring the strength of the base business.
Guidance
Accelerating. Raised from the previous $29.0 - $29.4 billion range. This implies robust high-single-digit growth for the core business, driven by Yeztugo and Trodelvy momentum.
Reversing. Slashed by roughly $9.50 per share from the prior $8.45 - $8.85 range. This massive revision is purely due to the $11.5 billion acquired IPR&D and financing charges related to the Arcellx, Ouro, and Tubulis transactions.
Accelerating. Raised by $400 million at the midpoint compared to previous guidance of $29.6 - $30.0 billion, absorbing the weakness in Cell Therapy and Veklury.
Key Questions
Cell Therapy Turnaround
With Yescarta down 14% and the segment declining for five straight quarters, what is the specific strategy to stabilize the legacy cell therapy business before Anito-cel launches?
M&A Synergy and ROI
After taking an $11.5B accounting hit on Arcellx, Tubulis, and Ouro, what are the key clinical or commercial milestones we need to see over the next 12-24 months to justify this massive capital allocation?
Yeztugo Cannibalization vs Expansion
Descovy surged 38% this quarter alongside the Yeztugo launch. As Yeztugo scales, how much of its growth do you expect to come from pure market expansion versus cannibalizing Descovy's existing PrEP share?